NIRBT Receives Grant to Develop Nanoscale Technologies for Glycan Analysis

Agilent Technologies Inc. (NYSE:A) and the Agilent Foundation today announced that Professor Pauline Rudd has received an Agilent Thought Leader Award in support of her emerging glycomics research.

The award includes a grant of funding and instruments to the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland. The goals of the research are to develop novel approaches to analyze protein glycosylation which will assist in the characterization of recombinant protein drugs, and to study potential glycan biomarkers associated with disease using liquid chromatography/mass spectrometry.

As leading experts in glycomics research, Professor Rudd’s group members have developed a new technology for high-throughput, detailed, quantitative glycan analysis at NIBRT’s Glycobiology Group Laboratory.

“Our partnership with Agilent will focus on multidimensional nanoscale LC-MS/MS separations for the comprehensive analysis of released oligosaccharides,” said Maurice N. Treacy, CEO of NIRBT. “The research will leverage the expertise of Agilent in separation sciences and NIBRT’s expertise in glycobiology to allow the development of novel technologies and complete solutions for rapid glycan analysis for use by the bio-pharmaceutical sector and in academia.”

The NIBRT Glycobiology Lab is at the forefront of fully automating technologies for glycan release and labelling, HPLC analysis, and exoglycosidase sequencing. Dedicated software and experimental databases enable computer assisted data analysis. The platform is allied to MS technologies to obtain further structural characterization and to provide a service that supports the drug development pipeline of leading pharmaceutical companies.

“Agilent is uniquely positioned to provide comprehensive analytical solutions for glycoprotein characterization and oligosaccharide analysis,” said Gustavo Salem, vice president and general manager of the Biological Systems Division at Agilent. “We are very eager to begin working with leading glycomics scientists at NIRBT to continue to drive research and discovery in this emerging field.”

Rudi Grimm, Ph.D., director of science and technology for Agilent’s Life Science Group, will work closely with Professor Rudd to provide technical expertise and serving as the primary contact with Agilent. Dr. Grimm created the opportunity for the grant by working with Agilent’s University Relations Program and Life Sciences Group to secure funding and instrumentation.

This is the first award from Agilent’s new Thought Leader Program, which promotes fundamental advances in the life sciences by contributing financial support, products and/or expertise to the research of influential thought leaders.

Source: http://www.agilent.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Agilent Technologies Inc.. (2019, March 18). NIRBT Receives Grant to Develop Nanoscale Technologies for Glycan Analysis. AZoNano. Retrieved on December 03, 2024 from https://www.azonano.com/news.aspx?newsID=18319.

  • MLA

    Agilent Technologies Inc.. "NIRBT Receives Grant to Develop Nanoscale Technologies for Glycan Analysis". AZoNano. 03 December 2024. <https://www.azonano.com/news.aspx?newsID=18319>.

  • Chicago

    Agilent Technologies Inc.. "NIRBT Receives Grant to Develop Nanoscale Technologies for Glycan Analysis". AZoNano. https://www.azonano.com/news.aspx?newsID=18319. (accessed December 03, 2024).

  • Harvard

    Agilent Technologies Inc.. 2019. NIRBT Receives Grant to Develop Nanoscale Technologies for Glycan Analysis. AZoNano, viewed 03 December 2024, https://www.azonano.com/news.aspx?newsID=18319.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.